Search Results
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
Eflornithine, TVI-BRAIN-1, LAM561 (2-OHOA), REC-2282, VT1021, VERZENIO (abemaciclib), PEMAZYRE (pemigatinib), Paxalisib (GDC-0084), BMX-001, Bizaxofusp (MDNA55), ITI-1000 (PP65 DC vaccine), SURVAXM, OKN-007, BERUBICIN, GLIOVAC/SITOIGANAP, IGV-001, BGB-290, EO2401, VBI-1901, TEMFERON, NOX-A12 (OLAPTESED PEGOL),
More news about: DelveInsight Business Research, LLP
Feb 17, 2026, 04:15 ET Shai Caleb Hirschson weist auf die nächste Herausforderung in der Musik- und Markeninnovation hin: Deep-Learning-Infrastruktur, die Marken über ihre einzigartige mDNA™ mit der Musik der Welt verbindet
https://eightsix.com/press/shai-caleb-hirschson-mdna-music-brand-innovationInformationen zu Shai Caleb HirschsonShai Caleb Hirschson ist ein preisgekrönter Musikproduzent,
More news about: EightSix
Feb 17, 2026, 04:15 ET Shai Caleb Hirschson Signals the Next Frontier in Music and Brand Innovation: Deep learning infrastructure connecting Brands to the World's Music Through Their Unique mDNA™
https://eightsix.com/press/shai-caleb-hirschson-mdna-music-brand-innovationAbout Shai Caleb HirschsonShai Caleb Hirschson is an award winning music producer, brand expert,
More news about: EightSix
Dec 04, 2025, 16:04 ET Mytheresa and Hani's Bakery Partner for an Immersive Holiday Gift Shop Experience in New York City
https://we.tl/t-PyrKX9MdNA 764 Madison Avenue, New York, NYOpen December 4–14, 2025Daily from 11:00 AM to 7:00 PMMedia
More news about: Mytheresa
Nov 25, 2025, 17:31 ET Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight
DelveInsight estimates, in 2024, among the mutation-specific prevalent cases of mitochondrial myopathies in the US, the highest number of cases was in the mDNA, while the lowest number of cases was seen in nDNA.Until mid-September 2025, mitochondrial myopathies lacked any disease-modifying options.
More news about: DelveInsight Business Research, LLP
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
are fueling demand. Additionally, the launch of therapies such as Zimberelimab + Domvanalimab (Arcus Biosciences/Gilead Sciences), HRO761 (Novartis), MDNA11 (Medicenna Therapeutics), RO7589831 (Roche), and others are expected to sustain robust growth in the coming years.
More news about: DelveInsight Business Research, LLP